Document Detail


Hydralazine, antinuclear antibodies, and the lupus syndrome.
MedLine Citation:
PMID:  6802356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The incidence of patients with positive antinuclear antibody test results rose during three years of treatment with hydralazine. At the end of that period over half of the patients (both rapid and slow acetylators) had titres exceeding 1/20, but the rate of rise was faster in the slow acetylators than in the rapid. There was a significant relation between the cumulative dose of hydralazine and the proportion of patients found to have antinuclear factors. Fewer black patients had positive test results than white. Patients whose antinuclear antibody test results changed fron negative to positive during the study showed this change five to 26 months after beginning treatment. Some patients showed a substantial fall in antinuclear antibody titre even though hydralazine was continued. From these findings patients in whom test results for antinuclear antibody became positive during treatment with hydralazine need not have the drug stopped unless they have clinical features of the lupus syndrome.
Authors:
R Mansilla-Tinoco; S J Harland; P J Ryan; R M Bernstein; C T Dollery; G R Hughes; C J Bulpitt; A Morgan; J M Jones
Related Documents :
2108246 - Clinical value of an integrated elisa system for the detection of 6 autoantibodies (ssd...
3839896 - The design and use of a charting system for automatic record keeping during extracorpor...
17534796 - Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hem...
8478856 - Treatment of systemic lupus erythematosus by prolonged administration of high dose intr...
23929146 - Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classificat...
23991226 - Association between chads2 score and the preventive effect of statin therapy on new-ons...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British medical journal (Clinical research ed.)     Volume:  284     ISSN:  0267-0623     ISO Abbreviation:  Br Med J (Clin Res Ed)     Publication Date:  1982 Mar 
Date Detail:
Created Date:  1982-06-21     Completed Date:  1982-06-21     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  8302911     Medline TA:  Br Med J (Clin Res Ed)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  936-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylation
Antibodies, Antinuclear / immunology*
Dose-Response Relationship, Drug
Female
Humans
Hydralazine / administration & dosage,  adverse effects*
Hypertension / drug therapy
Lupus Erythematosus, Systemic / chemically induced*,  immunology
Male
Phenotype
Syndrome
Chemical
Reg. No./Substance:
0/Antibodies, Antinuclear; 86-54-4/Hydralazine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neonatal screening for sickle haemoglobinopathies in Birmingham.
Next Document:  Missed injuries of the spinal cord.